Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 Vaccine Prioritisation in Japan and South Korea

June Young Chun, Hwichang Jeong, Philippe Beutels, Norio Ohmagari, Yongdai Kim, View ORCID ProfileShinya Tsuzuki
doi: https://doi.org/10.1101/2021.04.16.21255649
June Young Chun
1Department of Internal Medicine, National Cancer Center, Goyang, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hwichang Jeong
2Department of Statistics, Seoul National University, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Beutels
3Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norio Ohmagari
4Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
5AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongdai Kim
2Department of Statistics, Seoul National University, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ydkim0903@gmail.com stsuzuki@hosp.ncgm.go.jp
Shinya Tsuzuki
3Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
4Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
5AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shinya Tsuzuki
  • For correspondence: ydkim0903@gmail.com stsuzuki@hosp.ncgm.go.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background Due to a limited initial supply of COVID-19 vaccines, the prioritisation of individuals for vaccination is of utmost importance for public health. Here, we provide the optimal allocation strategy for COVID-19 vaccines according to age in Japan and South Korea.

Methods Combining national case reports, age-specific contact matrices, and observed periods between each stages of infection (Susceptible-Exposed-Infectious-Quarantined), we constructed a compartmental model. We estimated the age-stratified probability of transmission given contact (qi) using Bayesian inference method and simulated different vaccination scenarios to reduce either case numbers or death toll. We also performed sensitivity analyses on the proportion of asymptomatic cases and vaccine efficacy.

Findings The model inferred age-stratified probability of transmission given contact (qi) showed similar age-dependent increase in Japan and South Korea. Assuming the reported COVID-19 vaccine efficacy, our results indicate that Japan and South Korea need to prioritise individuals aged 20–35 years and individuals aged over 60 years, respectively, to minimise case numbers. To minimise the death toll, both countries need to prioritise individuals aged over 75 years. These trends were not changed by proportions of asymptomatic cases and varying vaccine efficacy on individuals under 20 years.

Interpretation We presented the optimal vaccination strategy for Japan and South Korea. Comparing the results of these countries demonstrates that not only the effective contact rates containing qi but also the age-demographics of current epidemic in Japan (dominance in 20s) and South Korea (dominant cases over 50s) affect vaccine allocation strategy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A2C3A01003550) and JSPS KAKENHI, Grant number 18K17369 and 20K10546.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All the data used in this study are publicly available, and therefore were regarded exempt from institutional review board assessment.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data and R codes used in this study are publicly available.

https://github.com/Hwichang/COVID-19-Vaccine-Prioritisation

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 Vaccine Prioritisation in Japan and South Korea
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 Vaccine Prioritisation in Japan and South Korea
June Young Chun, Hwichang Jeong, Philippe Beutels, Norio Ohmagari, Yongdai Kim, Shinya Tsuzuki
medRxiv 2021.04.16.21255649; doi: https://doi.org/10.1101/2021.04.16.21255649
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 Vaccine Prioritisation in Japan and South Korea
June Young Chun, Hwichang Jeong, Philippe Beutels, Norio Ohmagari, Yongdai Kim, Shinya Tsuzuki
medRxiv 2021.04.16.21255649; doi: https://doi.org/10.1101/2021.04.16.21255649

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (520)
  • Anesthesia (124)
  • Cardiovascular Medicine (1417)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10280)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2621)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1728)
  • Health Policy (788)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12078)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2451)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (489)
  • Occupational and Environmental Health (566)
  • Oncology (1318)
  • Ophthalmology (400)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2393)
  • Public and Global Health (4995)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (523)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (254)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)